Topica nails down $27 million Series B in pursuit of fungal infection treatment
This article was originally published in Scrip
While the yellow-green fungus that infects toenails, known as onychomycosis, may not be a sexy topic of discussion, the potential multibillion market for a drug to fill the current unmet need was enough of an alluring siren call to entice investors to lay down a bundle of cash to back Topica Pharmaceuticals' development of its experimental broad-spectrum topical antifungal agent luliconazole to treat the condition.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.